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OBJECTIVE — To assess two physician learning interventions designed to improve safety
and quality of diabetes care delivered by primary care physicians (PCPs).
RESEARCH DESIGN AND METHODS — This group randomized clinical trial in-
cluded57consentingPCPsandtheir2,020eligibleadultpatientswithdiabetes.Physicianswere
randomizedtonointervention(groupA),asimulatedcase-basedphysicianlearningintervention
(groupB),orthesamesimulatedcase-basedlearninginterventionwithphysicianopinionleader
feedback (group C). Dependent variables included A1C values, LDL cholesterol values, phar-
macotherapy intensiﬁcation rates in patients not at clinical goals, and risky prescribing events.
RESULTS — Groups B and C had substantial reductions in risky prescribing of metformin in
patientswithrenalimpairment(P0.03).ComparedwithgroupsAandC,physiciansingroup
B achieved slightly better glycemic control (P  0.04), but physician intensiﬁcation of oral
glucose-lowering medications was not affected by interventions (P  0.41). Lipid management
improved over time (P  0.001) but did not differ across study groups (P  0.67).
CONCLUSIONS — A simulated, case-based learning intervention for physicians signiﬁ-
cantly reduced risky prescribing events and marginally improved glycemic control in actual
patients. The addition of opinion leader feedback did not improve the learning intervention.
Reﬁnement and further development of this approach is warranted.
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D
espite recent improvements, the
qualityofdiabetescareintheU.S.is
far from what is recommended
based on current scientiﬁc evidence (1).
Moreover,recentstudies(2–4)document
frequent risky prescribing events in out-
patient diabetes care. Many health care
professionals, policy makers, and others
view diabetes care improvement and pa-
tient safety as an important national pri-
ority (5,6).
Diabetes care quality varies widely
across physicians, but factors that con-
tribute to this variation are poorly under-
stood(7).Qualitativestudiesindicatethat
physiciansareawareofdiabetescarestan-
dards. However, physicians frequently
fail to intensify therapy for patients not at
evidence-based clinical goals and often
use medications in potentially risky ways
(8,9). Past work (4) conﬁrms that physi-
cians often fail to 1) set appropriate clini-
cal goals, 2) initiate appropriate
pharmacotherapyinatimelyfashion,and
3) titrate pharmacotherapy until clinical
goalsareachieved.Variationincareatthe
physician level within a single medical
group supports the hypothesis that
change in physician behavior is a neces-
sarycomponentofcareimprovementand
may add beneﬁt even in medical groups
with advanced clinical decision support
and other ofﬁce care systems (10,11).
The difﬁculty of changing physician
behavior is widely assumed (12). Infor-
mation-based continuing medical educa-
tion has been shown to be largely
ineffective as a means of changing behav-
ior of physicians in ofﬁce practice. The
use of opinion leaders, audit and feed-
back, and ﬁnancial incentives are more
promising. However, each of these strat-
egies has signiﬁcant drawbacks or limita-
tions. Opinion leader interventions are
time consuming and expensive and may
be difﬁcult to replicate because of unique
propertiesofopinionleadersandpractice
environments (13). Audit and feedback
have limited effectiveness, consume a
great deal of effort and time, and may not
bewellsuitedtotailoringcarerecommen-
dations to speciﬁc needs of individual pa-
tients (14). Financial incentives are
promising but are expensive, somewhat
controversial, and difﬁcult to implement
over a wide range of clinical domains.
Simulated, case-based learning tools
offer a potentially effective approach to
physician behavior change. Theory sug-
gests that such an approach can be effec-
tive, especially for complex tasks (15,16).
However, most simulated learning ap-
proaches make little use of either 1) inter-
active interfaces that simulate patient
responsetophysicianmanagementovera
series of clinical encounters or 2) feed-
back tailored to observed physician treat-
ment patterns. The application of such
technology to change physician behavior
is in its infancy (17).
This study tests an innovative learn-
ing intervention designed to change phy-
sician behavior and improve safety and
quality of diabetes care. The simulated
learning intervention was tested alone
and in combination with opinion leader
feedback. The intervention used a famil-
iar electronic medical record interface
and allowed physicians to iteratively
manage a set of simulated patient cases
and receive electronic feedback on pre-
scribing behavior over a series of clinical
encounters. The intervention was inex-
pensive, portable, and took about1ho f
physician time.
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METHODS— A group randomized
trial was designed to test the hypothesis
that primary care physician (PCP) partic-
ipation in either of two study interven-
tions would improve safety or quality of
care delivered to actual patients with dia-
betes, relative to care delivered by control
group PCPs. Four principal dependent
variables were measured in actual pa-
tients: 1) change in A1C and LDL choles-
terol testing rates, 2) change in A1C and
LDL cholesterol levels, 3) rates of intensi-
ﬁcation of glucose or lipid medication
when patients are not achieving recom-
mended clinical goals, and 4) change in
risky prescribing events related to glyce-
mic control.
Study site and study subjects
The study was conducted at HealthPart-
ners Medical Group, an 18-clinic multi-
specialty group that provides care to
8,000 adults with diabetes. At the end of
2001, the mean A1C in the 90% of dia-
beticpatientswhohadanA1Ctestwithin
a year was 7.2%, and the mean LDL cho-
lesterol was 110 mg/dl, reﬂecting rela-
tively good baseline diabetes care (11).
Approximately 10% of adults with diabe-
tes consulted an endocrinologist each
year, most often for one visit (18). Addi-
tional information about the study site
and antecedent efforts to improve diabe-
tes care can be found in previous publica-
tions (11).
Sampling frame and recruitment of
PCPs
A sample of 122 potentially eligible PCPs
was identiﬁed. Physicians in the sample
were employed at least 20 h a week at
HealthPartnersMedicalGroupasof1Jan-
uary 2000 and provided care to a mini-
mum of 10 adult diabetic patients in
2000. Participating PCPs received com-
pensation of $100 for group A, $200 for
group B, or $600 for group C, predicated
on the differential time commitment to
each intervention. Before randomization,
67 consenting physicians were blocked
intogroupsofthreebasedon1)samespe-
cialty (family medicine or internal medi-
cine) and 2) whether they provided care
to 50 vs. 50 or more diabetic patients.
The intervention was done in early 2002,
and patient data to assess impact of the
intervention included data from 1 Janu-
ary 2001 to 31 December 2003.
Sampling frame and identiﬁcation of
adults with diabetes
Diabetic patients who received care from
study physicians were selected for analy-
sis if they met these criteria: 1) were en-
rolled in HealthPartners Medical Group
on 1 January 2000, 2) were at least 19
years of age on 1 January 2000, or 3) had
diagnosed diabetes in 2000 based on
meeting at least one of these criteria: two
or more outpatient ICD-9 diagnostic
codes 250.xx for diabetes or ﬁlled one or
more prescriptions for a diabetes-speciﬁc
drug. This diabetes identiﬁcation method
has estimated sensitivity 0.91, speciﬁcity
0.99, and positive predictive value 0.94
(19). To be included in the analysis, eligi-
ble patients had to have the same study-
participating PCP for 2 years before and 1
year after the intervention. Analysis
included 2,020 eligible adult diabetic
patients.
Description of interventions: control
group (group A)
PCPs randomized to this group com-
pleted baseline surveys but received no
intervention.
Learning intervention (group B)
Using software developed in previous
work (17,20), we provided each PCP in
group B with three clinical scenarios in
the same ﬁxed order. An electronic med-
ical record–like interface permitted mul-
tiple virtual patient-physician encounters
with each case in the presence of a re-
search assistant with no clinical training.
At each simulated patient encounter, the
PCP viewed history and physical exam
data, recorded impressions, and took a
series of actions that were not scripted
and could include ordering tests, making
referrals to specialists and educators, rec-
ommending diet and physical activity,
and initiating or titrating various medica-
tions for glucose, blood pressure, lipids,
or depression.
Actions could be taken at each sched-
uled visit or phone contact. Follow-up
was scheduled at any interval recom-
mended by the physician. At the next en-
counter, the patient’s clinical data (A1C,
LDL cholesterol, and blood pressure lev-
els and other data) reﬂected the effect of
actions taken in previous encounters, at-
tenuated by the time-dependent effects of
medications, lifestyle recommendations,
and recognition and treatment of depres-
sion. At each follow-up encounter with
the simulated patient, the physician re-
ceived“learningbydoing”feedbackinthe
form of patient responses to actions taken
in previous encounters. Each physician
dealt with three simulated cases over 60
min; each case was treated for a series of
simulated encounters over variable
lengths of simulated calendar time. At the
end of the three cases, each physician re-
ceived a printed feedback record of the
actions they had taken in each case com-
pared with actions taken by an expert
physician who performed the same cases.
Amorecompletedescriptionofthisinter-
vention software is available (17).
The patient cases seen by each physi-
cian were initialized for three important
clinical situations: 1) a newly diagnosed
type2diabeticpatientonnomedications,
2) a patient with contraindications to in-
sulin sensitizers (metformin and thiazo-
lidinediones) who required insulin
initiationandsubsequenttitration,and3)
a depressed individual with resulting low
adherence who required insulin titration.
Simulated cases plus physician
opinion leader intervention (group
C)
Physicians in group C received the same
threesimulatedcasesasgroupB,thesame
“learningbydoing”feedbackbasedonac-
tions taken, and the same printed feed-
backsummaryofactionstakencompared
with those of an expert physician. In ad-
dition, upon completion of the three
cases, group C physicians received 60
min of verbal interaction and feedback
from a physician opinion leader who ob-
served the physician while he/she per-
formed the simulations and used a
predesigned checklist at the completion
of the three cases as a tool to discuss po-
tentially problematic treatment issues, as
well as to give positive reinforcement for
good practice patterns that were ob-
served. Therefore, opinion leader feed-
back included both positive and negative
aspects of physician performance.
Dependent variables
A1C and LDL cholesterol test dates were
obtained from electronic clinical data-
bases and were used to assess physician
adherence to recommended frequency of
these tests in adults with diabetes.
Glycemic and lipid control were as-
sessed by comparing the last preinterven-
tion A1C and LDL cholesterol with the
last A1C and LDL cholesterol value in the
12-month postintervention period. All
A1C assays were performed for routine
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clinical chemistry laboratory. No changes
in assay procedures occurred during the
study. Details of the A1C assay (21) (nor-
mal range 4.5–6.1%; coefﬁcient of varia-
tion 0.058% at A1C 8.8%) and LDL
cholesterol assay (22) (calculated only af-
ter a 12-h fast and for triglycerides 400
mg/dl) are described elsewhere (11).
Medication moves (including initia-
tion or titration of glucose or lipid drugs)
were determined in the 12-month
postintervention period for all diabetic
patientswithabaselineA1C7%orLDL
cholesterol 100 mg/dl. Medication
moves were identiﬁed based on drug
doses and prescription ﬁlls during de-
ﬁned periods of time using pharmacy
claims data. Because insulin is often dis-
cardedmonthlyduetoexpiration,insulin
claims data do not accurately reﬂect ac-
tual usage; therefore, insulin dose titra-
tion was excluded from the glucose move
variable.
The learning intervention focused on
one risky prescribing event: use of met-
formin in patients with serum creatinine
values 1.5 mg/dl. By design, the learn-
ing intervention did not address risky use
of metformin in patients with congestive
heart failure (CHF).
Independent variables
Analysis was limited to two levels (pa-
tients nested within physicians) because
intraclass correlation coefﬁcients at the
clinic level were small, consistent with
previously reported data. Patient-level in-
dependent variables obtained from elec-
tronic databases included age, sex, and
baseline comorbidity score (23). Physi-
cian-levelindependentvariablesobtained
from electronic databases included age,
sex, specialty, years of experience, and
number of diabetic patients.
Analytic approach
Thisgrouprandomizedtrialwasanalyzed
as a nested (patients nested within physi-
cians) cohort pretest-posttest control
groupdesignwhenthevariablesbeingex-
amined were available both pre- and
postintervention (e.g., A1C value). In this
analysis,thecoefﬁcientandPvalueforthe
time-by-conditioninteractiontermtested
the intervention effect by examining dif-
ferencesincondition(groupsA,B,andC)
and change over time. In some instances,
post hoc contrasts were utilized to com-
pare change over time in speciﬁc combi-
nations of conditions (24). Nested
analysis of postintervention data with re-
gression adjustment for patient age, sex,
andcomorbidityscorewasusedwhenex-
amining variables measured only postint-
ervention (e.g., medication moves). In
this type of analysis, the intervention ef-
fect was tested by the coefﬁcient and P
value for condition. This analytic ap-
proach was utilized as an alternative
method to the time-by-condition analysis
in order to assess the effect of study arm
after control for patient covariates. Since
results using this method were similar to
those obtained in the time-by-condition
analysis, we report only the time-by-
condition results.
Mixed-effects models were estimated
with SAS Proc Mixed. For dichotomous
outcomes (e.g., test rates), Proc Mixed
was also used with and without the Glim-
mix macro. Because results were similar
with and without this macro, we report
themorereadilyinterpretable(24)results
frommodelswithouttheGlimmixmacro.
A priori sample size calculations as-
sumed 20 providers with 30 diabetic pa-
tients each (600 diabetic patients per
study arm) would be available for analy-
sis. Effective patient sample size was esti-
mated as n  311 per arm due to
clustering using a measured intraclass
correlation coefﬁcient  0.032 based on
eligible physicians. This study was de-
Table 1—Description of patients and PCPs
Intervention groups
P All A B C
Patients (n) 2,020 691 725 604
Age as of intervention date (means  SD) 64.0  13.0 64.2  12.8 63.4  13.2 64.5  13.1 0.24
Age 65 years (%) 48.6 49.4 45.7 51.2 0.11
Female (%) 42.0 44.6 40.4 41.1 0.24
Coronary heart disease (in 12 months preintervention) (%) 14.0 11.9 16.7 13.3 0.03
Hypertension (in 12 months preintervention) (%) 60.2 61.4 59.6 59.4 0.72
Charlson score (in 12 months preintervention) (means  SD) 2.0  1.6 1.9  1.5 2.1  1.6 2.0  1.7 0.04
Depression diagnosis (in 12 months preintervention) (%) 7.5 7.4 8.1 7.0 0.71
Preintervention A1C (median, last value in 12 months
preintervention) 7.20 7.10 7.30 7.10 0.09
Postintervention A1C (median, last value in 12 months
preintervention) 7.20 7.20 7.20 7.30 0.79
Preintervention LDL cholesterol (median, last value in 12 months
preintervention) 102 102 103 101 0.76
Postintervention LDL cholesterol (median, last value in 12 months
preintervention) 100 100 100 99 0.99
Physicians (n) 5 7 1 91 91 9
Female (%) 26 37 26 16 0.34
Physician age (mean) 48.5 49.6 47.6 48.0 0.76
Years since graduation (mean) 21.7 22.7 20.8 21.5 0.81
80% time spent on patient care (%) 75 77 75 72 0.96
Family practitioners 44% 47% 42% 42% 0.93
Number of eligible diabetes patients (means  SD) 35.4  21.2 36.3  23.0 38.2  22.0 31.8  19.1 0.64
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difference of 0.3% between study arms,
with a two-tailed 0.05. This study
was reviewed, approved in advance, and
monitored by the HealthPartners Institu-
tional Review Board, project no. 00-016.
Informed consent was obtained from all
physician study subjects. This study is
registered as no. NCT00262704 at www.
clinicaltrials.org.
RESULTS— We were able to recruit
50% of eligible PCPs to participate in
the study. Physician attrition occurred
due to noncompletion of the physician
baseline survey (n  1), withdrawal from
the study (n  1), noncompletion of the
intervention (n  3), and departure from
the medical group during the study pe-
riod (n  3). Two physicians were ex-
cluded from analysis because they had
insufﬁcient postintervention diabetic pa-
tients available due to changes in job re-
sponsibilities. Attrition occurred evenly
acrossrandomizedgroups,andﬁnalanal-
ysis included 19 physicians in each
group.Over97%ofthosewhocompleted
the learning intervention rated their satis-
faction with the interventions as excellent
or very good after completing the simu-
lated cases.
Table 1 characterizes patients and
physicians in each of the three study
arms. Randomization at the physician
level resulted in similar patient samples
except that patients of physicians in
group B more often had coronary artery
disease and higher Charlson scores. Phy-
sician attributes did not differ by group.
Table2showschangesinA1Ctesting
and A1C levels. There was a signiﬁcant
change in A1C level from before to after
intervention, and the time-by-group in-
teraction term was signiﬁcant (P  0.04),
indicatingsigniﬁcantgroupdifferencesin
change in A1C levels over time. A1C val-
ues of patients of physicians in group B
declined,whiletheA1Cvaluesofpatients
of physicians in groups A (control) and C
increased. An analogous model (data not
shown) predicting postintervention A1C
levelsfromeachgroupandcontrollingfor
preintervention A1C, patient age, sex,
and preintervention Charlson score
showed similar results.
Table 2 also shows results of the anal-
ysis restricted to patients on insulin for
120 days in both the pre- and postint-
ervention periods. The overall time-by-
condition term indicates no signiﬁcant
postintervention group differences in
A1C change in insulin-treated patients.
PatientsnotoninsulinhadanoverallA1C
increase of 0.13% from pre- to postinter-
vention, with no differences by group
(P  0.10). Most of the A1C advantage of
group B patients was concentrated in the
subgroup using insulin.
Table 2 also shows that LDL choles-
terol values improved over time (P 
0.001), with no signiﬁcant differences in
LDL cholesterol test rates (P  0.30) or
LDL cholesterol values (P  0.67) across
studygroups.Statinuse(P0.0001)and
ﬁbrate use (P  0.001) increased over
time with no differences across study
groups (time-by-group P  0.22 for
statins and P  0.78 for ﬁbrates).
Among patients above A1C goal dur-
ing the preintervention time period (n 
907), the rate of postintervention initiation
or titration of blood glucose–lowering
medications was 31.5% in group A,
Table 2—Change in A1C and LDL cholesterol testing rates and values
All
Intervention group
AB C
Control Learning cases Cases plus expert
A1C testing rate (n) 2,020 691 725 604
12 months preintervention (%) 90.8 90.9 91.6 89.6
12 months postintervention (%) 89.2 90.2 88.9 88.2
Change in A1C test rate (%) 1.6 0.7 2.7 1.4
Time (P  0.07) Condition P  0.79 Time-by-condition P  0.63
Last A1C value (mean) (n) 1,686 578 601 507
12 months preintervention 7.38 7.33 7.47 7.32
12 months postintervention 7.45 7.39 7.46 7.50
Change in A1C value (%) 0.07 0.06 0.01 0.18
Time P  0.009 Condition P  0.58 Time-by-condition P  0.04
Last A1C value, patients on insulin (mean) (n) 526 172 199 155
12 month preintervention 7.95 7.87 8.02 7.95
12 month postintervention 7.92 7.88 7.85 8.03
Change in A1C value 0.03 0.01 0.17 0.08
Time P  0.69 Condition P  0.74 Time-by-condition P  0.15
LDL cholesterol testing rate (n) 2,020 691 725 604
12 months preintervention (%) 71.6 74.2 70.2 70.2
12 months postintervention (%) 73.6 73.7 74.9 72.1
Change in LDL cholesterol test rate (%) 2.0 0.5 4.7 1.9
Time P  0.15 Condition P  0.76 Time-by-condition P  0.30
Last LDL cholesterol value (mean) (n)* 1,178 412 419 347
12 month preintervention 106.0 107.0 106.3 104.5
12 month postintervention 102.6 102.9 103.9 100.8
Change in LDL cholesterol value 3.4 4.1 2.4 3.7
Time P  0.001 Condition P  0.63 Time-by-condition P  0.67
*Those with test values both pre- and postintervention. †Those with A1C values and on insulin both pre- and postintervention.
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(P  0.41). Insulin titration could not be
ascertainedfromdatasources.Amongpa-
tients with their most recent preinterven-
tion LDL cholesterol 100 mg/dl (n 
701),initiationandtitrationoflipidmed-
ications was 20.8% in group A, 24.2% in
group B, and 21.8% in group C (P 
0.66). Among patients with their most re-
cent preintervention blood pressure
130/80 mmHg (n  949), the rate of
postintervention initiation or titration of
blood pressure–lowering medications
was 27.3% in group A, 24.7% in group B,
and 28.2% in group C (P  0.61). Thus,
the intervention did not signiﬁcantly in-
crease rates of treatment intensiﬁcation.
Table 3 provides data on risky pre-
scribing events. While the time-by-
condition term was only marginally
signiﬁcant (P  0.08), a contrast of the
control condition (group A) with the
combined intervention groups (B plus C)
showed a signiﬁcant effect (P  0.03) in
favor of groups B and C for reduction in
metformin use in patients with a renal
contraindication to metformin use. No
changes by group in metformin use fol-
lowing a CHF diagnosis (P  0.36) were
observed,consistentwiththefactthatthis
issue was not highlighted in the clinical
cases.
CONCLUSIONS — Despitethebrev-
ity of the learning interventions, we ob-
served signiﬁcant effects on diabetes care
delivered to actual patients in the 12
months after each intervention was com-
pleted. First, both intervention groups
showed an 60% decline in risky met-
formin use in patients with reduced renal
function compared with the control
group. Notably, there was no change in
risky use of metformin in CHF patients,
which was a clinical issue not included in
the learning cases. Second, patients of
physicians in group B had more desirable
patternsofglycemiccontrolpostinterven-
tion than patients in the other groups. Fi-
nally, while lipid control improved in all
groups, no differences in LDL cholesterol
levels were observed across intervention
groups.
Based on postintervention changes
in treatment patterns in real patients,
we conclude that different things were
learned by the physicians in our two
intervention groups (B and C). The part
of each intervention that was common
to both physician groups was com-
prised of three simulated cases, two of
which focused on insulin initiation and
titration. The data suggest, but do not
prove, that physicians in group B
learned to make additional insulin titra-
tion moves for their patients who were
already on insulin (see Table 2), and
better management of insulin-treated
patientsledtotheA1Cimprovementwe
observed in group B.
The physician opinion leader did not
enhance the simulated learning interven-
tion.Thereasonforthisisunclearbutcould
have included the following: 1) the opinion
leader focused on less-relevant clinical is-
sues than the simulated program itself, 2)
thepresenceofanotherphysicianobserving
increased anxiety of the physician learner,
or3)thepositivereinforcementoftheopin-
ion leader led the providers to believe they
did not need to change their clinical behav-
iors with actual patients. This ﬁnding is en-
couraging from a cost perspective because
opinion leader time adds signiﬁcant cost to
the intervention.
There are a number of factors that
limit the interpretation of these data.
First, the study was conducted among
PCPs at a single medical group, and gen-
eralization of results to other settings is
not assured. Second, the lack of data on
insulin intensiﬁcation and patient medi-
cation adherence constrains our analysis
of how interventions mediated their ef-
fects. Third, because blood pressure val-
ueswerenotyetelectronicallyavailableat
the time of data analysis, we were unable
toassesstheimpactoftheinterventionon
changes on blood pressure, although the
learning cases included blood pressure
management issues. Fourth, the study
was conducted at a site with relatively
goodbaselinediabetescare,andinterven-
tion impact may differ in settings where
baseline care is poorer. Finally, the study
design did not assess whether augmenta-
tion of the interventions using additional
cases or periodic repetition could further
amplify the beneﬁts of this limited inter-
vention involving only three diabetic case
subjects.
Despite some limitations, study re-
sults are interesting and important. Safety
improvement was substantial, and al-
though glycemic control improvements
were modest, few previous physician-
learning interventions have reported
positive results (25). This learning tech-
nology could be more effective if simu-
lated cases were customized for each
individual physician based on analysis of
patterns of care in electronic health
records. Further experimentation with
this intervention strategy in other settings
and for other clinical conditions is also
warranted. Effective physician learning
interventions such as these, which are
brief, enjoyable, and scalable, may com-
plement other care improvement strate-
gies and may contribute to the essential
goalofimprovingthesafetyandqualityof
chronic disease care.
Table 3—Change in risky metformin-prescribing events
All
Intervention group
AB C
Metformin ﬁll among those with a prior serum
creatinine test 1.5 mg/dl (n) 264 77 100 87
12 months preintervention (%) 13.8 6.4 14.8 19.3
12 months postintervention (%) 6.7 6.4 4.8 9.0
Change in metformin ﬁll rate (%) 7.1 0 10.0 10.3
Time P  0.002 Condition P  0.23 Time-by-condition P  0.08
Metformin ﬁll following a CHF diagnosis (n) 259 73 107 79
12 months preintervention (%) 16.6 15.8 15.3 19.0
12 months postintervention (%) 12.6 16.4 11.6 10.5
Change in metformin ﬁll rate (%) 4.0 0.6 3.7 8.5
Time P  0.11 Condition P  0.88 Time-by-condition P  0.36
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